RS57545B1 - Novi derivati indola i pirola, postupak njihove izrade i farmaceutske kompozicije koje ih sadrže - Google Patents
Novi derivati indola i pirola, postupak njihove izrade i farmaceutske kompozicije koje ih sadržeInfo
- Publication number
- RS57545B1 RS57545B1 RS20180839A RSP20180839A RS57545B1 RS 57545 B1 RS57545 B1 RS 57545B1 RS 20180839 A RS20180839 A RS 20180839A RS P20180839 A RSP20180839 A RS P20180839A RS 57545 B1 RS57545 B1 RS 57545B1
- Authority
- RS
- Serbia
- Prior art keywords
- methyl
- compound
- phenyl
- formula
- carbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1357277A FR3008978A1 (fr) | 2013-07-23 | 2013-07-23 | "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
| PCT/FR2014/051884 WO2015011396A1 (fr) | 2013-07-23 | 2014-07-22 | Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP14758604.4A EP3027602B1 (fr) | 2013-07-23 | 2014-07-22 | Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS57545B1 true RS57545B1 (sr) | 2018-10-31 |
Family
ID=49911607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20180839A RS57545B1 (sr) | 2013-07-23 | 2014-07-22 | Novi derivati indola i pirola, postupak njihove izrade i farmaceutske kompozicije koje ih sadrže |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9765056B2 (OSRAM) |
| EP (2) | EP3168217A1 (OSRAM) |
| JP (1) | JP6458028B2 (OSRAM) |
| KR (1) | KR102337149B1 (OSRAM) |
| CN (1) | CN105408321B (OSRAM) |
| AR (1) | AR099914A1 (OSRAM) |
| AU (1) | AU2014294866B2 (OSRAM) |
| BR (1) | BR112016001333B1 (OSRAM) |
| CA (1) | CA2917965C (OSRAM) |
| CY (1) | CY1120475T1 (OSRAM) |
| DK (1) | DK3027602T3 (OSRAM) |
| EA (1) | EA028609B1 (OSRAM) |
| ES (1) | ES2687475T3 (OSRAM) |
| FR (1) | FR3008978A1 (OSRAM) |
| HK (1) | HK1218753A1 (OSRAM) |
| HR (1) | HRP20181333T1 (OSRAM) |
| HU (1) | HUE039507T2 (OSRAM) |
| LT (1) | LT3027602T (OSRAM) |
| MX (1) | MX364479B (OSRAM) |
| NZ (1) | NZ715847A (OSRAM) |
| PL (1) | PL3027602T3 (OSRAM) |
| PT (1) | PT3027602T (OSRAM) |
| RS (1) | RS57545B1 (OSRAM) |
| RU (1) | RU2693404C2 (OSRAM) |
| SG (1) | SG11201600004SA (OSRAM) |
| SI (1) | SI3027602T1 (OSRAM) |
| TW (1) | TW201504224A (OSRAM) |
| UA (1) | UA117020C2 (OSRAM) |
| UY (1) | UY35653A (OSRAM) |
| WO (1) | WO2015011396A1 (OSRAM) |
| ZA (1) | ZA201600415B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105237509A (zh) * | 2015-11-20 | 2016-01-13 | 江苏瑞邦农药厂有限公司 | 一种2,2-二氟-1,3-苯并二恶茂的合成方法 |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| US11628159B2 (en) | 2017-01-10 | 2023-04-18 | Eth Zurich | Cell-protective compounds and their use |
| JP6877722B2 (ja) | 2017-03-31 | 2021-05-26 | 国立大学法人 東京大学 | ノロウイルス抗体 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN108409580A (zh) * | 2018-02-01 | 2018-08-17 | 浙江工业大学 | 一种苄胺类化合物的合成方法 |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| EP4525927A1 (en) | 2022-05-20 | 2025-03-26 | Novartis AG | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2298832T3 (es) | 2003-10-24 | 2008-05-16 | Glaxo Group Limited | Compuestos heterociclicos. |
| TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| AU2005277223C1 (en) * | 2004-08-20 | 2009-05-21 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof |
| GB0522908D0 (en) | 2005-11-10 | 2005-12-21 | Merck Sharp & Dohme | Therapeutic agents |
| EP2714681B1 (en) * | 2011-05-25 | 2015-06-24 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
| MX2014007731A (es) * | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
| EA201491265A1 (ru) * | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию |
| MX2014007729A (es) * | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
| EA201491259A1 (ru) * | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания |
| US9126979B2 (en) * | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| FR2986002B1 (fr) | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-07-23 FR FR1357277A patent/FR3008978A1/fr not_active Withdrawn
-
2014
- 2014-07-08 UY UY35653A patent/UY35653A/es unknown
- 2014-07-21 AR ARP140102679A patent/AR099914A1/es unknown
- 2014-07-22 CN CN201480041559.7A patent/CN105408321B/zh not_active Expired - Fee Related
- 2014-07-22 LT LTEP14758604.4T patent/LT3027602T/lt unknown
- 2014-07-22 SG SG11201600004SA patent/SG11201600004SA/en unknown
- 2014-07-22 KR KR1020167004577A patent/KR102337149B1/ko not_active Expired - Fee Related
- 2014-07-22 MX MX2016000900A patent/MX364479B/es active IP Right Grant
- 2014-07-22 SI SI201430784T patent/SI3027602T1/en unknown
- 2014-07-22 AU AU2014294866A patent/AU2014294866B2/en not_active Ceased
- 2014-07-22 HK HK16106759.0A patent/HK1218753A1/zh unknown
- 2014-07-22 TW TW103125162A patent/TW201504224A/zh unknown
- 2014-07-22 HU HUE14758604A patent/HUE039507T2/hu unknown
- 2014-07-22 NZ NZ715847A patent/NZ715847A/en not_active IP Right Cessation
- 2014-07-22 EP EP16201228.0A patent/EP3168217A1/fr not_active Withdrawn
- 2014-07-22 CA CA2917965A patent/CA2917965C/fr active Active
- 2014-07-22 RU RU2016106002A patent/RU2693404C2/ru active
- 2014-07-22 BR BR112016001333-6A patent/BR112016001333B1/pt not_active IP Right Cessation
- 2014-07-22 DK DK14758604.4T patent/DK3027602T3/en active
- 2014-07-22 HR HRP20181333TT patent/HRP20181333T1/hr unknown
- 2014-07-22 EA EA201600121A patent/EA028609B1/ru unknown
- 2014-07-22 PL PL14758604T patent/PL3027602T3/pl unknown
- 2014-07-22 UA UAA201601398A patent/UA117020C2/uk unknown
- 2014-07-22 RS RS20180839A patent/RS57545B1/sr unknown
- 2014-07-22 EP EP14758604.4A patent/EP3027602B1/fr active Active
- 2014-07-22 WO PCT/FR2014/051884 patent/WO2015011396A1/fr not_active Ceased
- 2014-07-22 JP JP2016528587A patent/JP6458028B2/ja not_active Expired - Fee Related
- 2014-07-22 US US14/905,877 patent/US9765056B2/en not_active Expired - Fee Related
- 2014-07-22 PT PT147586044T patent/PT3027602T/pt unknown
- 2014-07-22 ES ES14758604.4T patent/ES2687475T3/es active Active
-
2016
- 2016-01-12 ZA ZA2016/00415A patent/ZA201600415B/en unknown
-
2017
- 2017-08-14 US US15/676,154 patent/US10662173B2/en active Active
-
2018
- 2018-07-19 CY CY20181100757T patent/CY1120475T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS57545B1 (sr) | Novi derivati indola i pirola, postupak njihove izrade i farmaceutske kompozicije koje ih sadrže | |
| US11028070B2 (en) | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | |
| KR20190012167A (ko) | 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도 | |
| RS55838B1 (sr) | Novi derivati pirola, postupak njihovog dobijanja i farmaceutske kompozicije koje ih sadrže | |
| CN110650959B (zh) | 治疗化合物和组合物及其使用方法 | |
| JP2014509660A (ja) | ＰＤＫ１キナーゼの阻害剤としての置換３−（１Ｈ−ベンゾ｛ｄ｝イミダゾール−２−イル）−１Ｈ−インダゾール類似体 | |
| CN119768398A (zh) | 抑制和/或诱导kras蛋白降解的杂环化合物 | |
| RS56451B1 (sr) | Novi derivati indolizina, postupak njihove proizvodnje i farmaceutske kompozicije koje ih sadrže | |
| CA3198096A1 (en) | Aryl derivatives for treating trpm3 mediated disorders | |
| CN102316738A (zh) | 作为激酶抑制剂的酰胺类 | |
| EP4198036A1 (en) | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof | |
| ES2866324T3 (es) | Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria | |
| JP2025541695A (ja) | 置換１－フェニル－３，４－ジヒドロピリド［３，４－ｄ］ピリミジン－２－オン誘導体 | |
| CN116783166B (zh) | 二甲酰胺类化合物、其制备方法及其在医药上的应用 | |
| HK40093207A (en) | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof | |
| WO2025140655A1 (en) | Heteroaryl compounds as multi-target protein kinase inhibitors | |
| CN101321762A (zh) | 三环内酰胺衍生物、它们的制备和作为药剂的应用 |